Deals and IPOs

M&A activity is a defensive play: Trader

We are at a dispersion inflection point: Pro

A recent wave of megamergers is a sign that companies are on the defensive, an NYSE trader said Thursday.

"They are merging because it's a defensive play, they don't want to use that money to be creative and build a new environment," Empire Executions' Peter Costa told CNBC's "Closing Bell."

Costa said companies want to grow, but not by investing in their own products, instead opting to take over other companies. "I think if that money is going to be spent it should be spent building and employing people and building new businesses," he added.

Among the most recent news on megamergers is a possible deal between Allergan and Pfizer and another between Walgreens and Rite Aid.

Carl Icahn at Delivering Alpha 2015 in New York.
Icahn warns on tax reform again amid Pfizer talks
Traders on the floor of the New York Stock Exchange.
This index signaled the 2000 and 2007 crashes—and it's falling again
Pfizer headquarters in New York.
Allergan confirms talks regarding possible deal with Pfizer

Jim Keenan, head of credit at BlackRock, said deals will continue as companies look to expand in a low-growth environment.

"You see these megadeals as a way to create cost synergies because they [companies] don't have expectations of a significant growth trend, so where they are creating shareholder value is through these deals," he said in the same interview.

"This is a point of time where there will be a lot of dispersion; in a low-growth environment you are going to have your winners and losers."